Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
NCT ID: NCT06577090
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
136 participants
INTERVENTIONAL
2024-08-22
2027-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
NCT04969939
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
NCT03552757
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
NCT02453711
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
NCT06041217
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
NCT03574584
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nimacimab injection
Nimacimab injection 200 mg
Nimacimab injection
Nimacimab injection 200 mg
Nimacimab placebo injection
Matching nimacimab placebo injection
Nimacimab placebo injection
matching nimacimab placebo injection
Semaglutide injection + Nimacimab injection 200 mg
Semaglutide injection administered according to dose escalation described in semaglutide prescribing information plus concomitant administration of Nimacimab Injection 200 mg
Nimacimab injection
Nimacimab injection 200 mg
semaglutide injection
semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg + nimacimab 200 mg
Semaglutide injection + Nimacimab placebo injection
Semaglutide injection administered according to dose escalation described in semaglutide Prescribing Information plus concomitant administration of Nimacimab Injection or matching placebo injection
Nimacimab placebo injection
matching nimacimab placebo injection
semaglutide injection
semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg + nimacimab 200 mg
Open-label 300 mg Nimacimab injection (study extension)
Weekly nimacimab injection 300 mg open-label (study extension)
Nimacimab 300 mg injection
Nimacimab injection 300 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nimacimab injection
Nimacimab injection 200 mg
Nimacimab placebo injection
matching nimacimab placebo injection
semaglutide injection
semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg + nimacimab 200 mg
Nimacimab 300 mg injection
Nimacimab injection 300 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place to 65 years, inclusive, at the time of signing the informed consent.
3. Male, female, and/or nonbinary participants.
4. Have Body Mass Index (BMI) of
1. ≥ 30 kg/m2 to ≤ 45 kg/m2 OR
2. ≥ 27 kg/m2 and \< 30 kg/m2 with clinically confirmed diagnosis of at least 1 of the following weight-related co-morbidities:
i. dyslipidemia: on lipid-lowering medication or having low-density lipoprotein (LDL) ≥ 160 mg/dL (4.1 mmol/L) or triglycerides ≥ 150 mg/dL (1.7 mmol/L) or high-density lipoprotein (HDL) \< 40 mg/dL (1.0 mmol/L) for men or HDL \< 50 mg/dL (1.3 mmol/L) for women at screening.
ii. cardiovascular disease: (for example, ischemic cardiovascular disease, New York Heart Association \[NYHA\] Functional Classification Class I-II heart failure).
iii. obstructive sleep apnea syndrome (Salzano 2021).
iv. controlled arterial hypertension with systolic blood pressure (SBP) \< 150 mmHg or diastolic blood pressure (DBP) \< 90 mmHg.
5. Have an HbA1c \<6.5% at screening.
6. Have had a stable body weight for the 3 months prior to screening (no more than 5% body weight gain and/or loss).
7. If on cardiovascular, anti-hypertensive, must be controlled controlled on a stable dose for 3 months prior to randomization.
8. If on hormone replacement therapy, must be on a stable dose for at least 3 months prior to screening, including use of thyroxine.
9. Females of childbearing potential must agree:
1. to use an approved method of contraception from screening throughout the study and for at least 90 days after the last dose of study drug.
2. to not donate ova from screening throughout the study and for at least 90 days after the last dose of study drug.
3. have a negative pregnancy test at screening and Day 0.
10. Male participants who are (hetero) sexually active must agree that he and his partner will each use an approved method of contraception from screening throughout the study and for at least 90 days after the last dose of study drug.
11. Agreement in male participants to not donate sperm from screening throughout the study and for at least 90 days after the last dose of study drug.
Exclusion Criteria
2. Have at least 1 laboratory value suggestive of diabetes during screening, including 1 or more of HbA1c ≥ 6.5% (48 mmol/mol), fasting serum glucose ≥ 126 mg/dL (7.0 mmol/L), or random glucose ≥ 200 mg/dL (11.1 mmol/L).
3. Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \> 1 year prior to screening).
4. Have obesity induced by other disorders (for example, Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome) or use of systemic corticosteroids or uncontrolled hypothyroidism. (Hypothyroidism on stable treatment is allowed if thyroid stimulating hormone (TSH) measure within the last 3 months of screening is within normal limits).
5. Have had at any time or plan to have endoscopic and/or device-based therapy for obesity including but not limited to the following:
1. Mucosal ablation,
2. Gastric artery embolization,
3. Intragastric balloon, OR
4. Duodenal-jejunal endoluminal liner
6. Surgery of any kind within 3 months prior to Day 0 (Baseline) with the exception of minor procedures or determined by the Investigator to be clinically relevant for participation in the study, or any planned surgery during the study.
7. Renal impairment as estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2, calculated at screening using the recommended method for estimating eGFR in adults from the National Kidney Foundation Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI 2021) equation (Charles 2024).
8. Acute kidney injury or dialysis within the last 3 months prior to the screening visit
9. Current malignancy with the exception of participants with basal cell carcinoma of this skin, suqamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy.
10. Positive results at screening that indicate an active virological infection at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus.
11. Previous organ or bone marrow transplant.
12. History and/or confirmed seizure disorder; reports febrile and/or idiopathic seizures occurring within the past 2 years.
13. Unstable cardiovascular disease as determined by the Investigator or medical history of myocardial infarction or arterial thromboembolic events within 3 months prior to screening or severe or unstable angina, NYHA Class III or IV disease, or a 12-lead ECG showing QTc interval (Fridericia's formula) \>450 msec (males) or \>470 msec (females), any tachyarrhythmia, pathologic Q waves, or any other abnormality deemed clinically significant in the opinion of the investigator.
14. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participants' participation for the full duration of the study, or is not in the best interest of the participants to participate in the opinion of the Investigator.
15. Have history of any of the following:
1. Major Depressive Disorder (MDD)
2. A lifetime history of suicide attempts
3. Other severe psychiatric disorder(s) (e.g., schizophrenia, bipolar disorder, etc.)
4. Use of anti-depressant medication
16. Have a Patient Health Questionnaire-9 (PHQ-9) score ≥ 10 at screening and/or Day 0 (Baseline).
17. At screening or Day 0 (Baseline) have any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) or any suicidal behavior in the lifetime or previous month.
18. History or presence of drug abuse (including medicinal and recreational marijuana use) within the 1 year prior to Day 0 (Baseline) or urine drug assay at screening or Day 0 (Baseline) positive (includes: amphetamines, barbiturates, cocaine metabolites, opiates, benzodiazepines, and cannabinoids).
19. Prior exposure to study drugs
1. Nimacimab injection
2. Glucagon-like peptide-1 (GLP-1) agonist.
3. Allergy to active or inactive component of Nimacimab
4. Allergy to active or inactive component(s) of GLP-1 agonist
20. Female participants who are pregnant or breastfeeding or expecting to conceive children within the projected duration of the study.
21. Aspartate aminotransferase (AST) or alanine transaminase (ALT) \> 3 × upper limit of normal (ULN) at screening. One repeat test may be allowed within 7 days of the receiving the result, at the discretion of the Investigator.
22. Absolute neutrophil count ≤ 1.5 × 109/L.
23. Platelets ≤ 120 × 109/L.
24. Hemoglobin (Hgb) \< 13.5 g/dL in males and \< 12 g/dL in females.
25. Currently or have participated in a study of an investigational product or used an investigational device within 12 weeks and/or 5 times the half-life of the investigational product prior to the (Day 0, Baseline) first dose of study treatment.
26. Current use of any medication that is known to cause weight loss or participation in a structured weight loss program within the last 6 months prior to screening
27. Employees of the Sponsor, contract research organization (CO) involved in the conduct of the study, or investigational site, or immediate family members of the employees.
28. History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces \[150 mL\] of wine or 12 ounces \[360 mL\] of beer of 1.5 ounces \[45 mL\] of hard liquor) within 6 months of screening.
Study Extension Eligibility Criteria
Participants are eligible to be included in the extension only if all the following criteria apply:
1. Completed Week 26 of the Main study including Week 25 on study treatment. Participants who completed Week 26 of the Main study but discontinued study treatment prior to that visit are not eligible to participate.
1. Participants in the combination arms (Nimacimab Injection or placebo + Semaglutide) of the Main study must roll over within 4 weeks of Main study Week 26
2. Participants in the monotherapy arms (Nimacimab Injection or placebo) of the Main study can roll over anytime after they have completed Week 26 on study treatment but before completing the 13-week follow-up period.
2. Does not have any condition that interferes with the ability to complete the Extension in the judgment of the investigator.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Skye Bioscience, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chief Development Officer
Role: STUDY_DIRECTOR
Skye Bioscience, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pinnacle Research Group
Anniston, Alabama, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
ACCEL Research Sites
Atlanta, Georgia, United States
Center for Advanced Research & Education
Gainesville, Georgia, United States
L-MARC Research Center
Louisville, Kentucky, United States
Be Well Clinical Studies
Lincoln, Nebraska, United States
Palm Research Center
Las Vegas, Nevada, United States
ActivMed Practices & Research
Portsmouth, New Hampshire, United States
Weill Cornell Medicine
New York, New York, United States
Accellacare of Wilmington
Wilmington, North Carolina, United States
Lillestol Research, LLC
Fargo, North Dakota, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
Be Well Clinical Studies
Round Rock, Texas, United States
Charlottesville Medical Research
Charlottesville, Virginia, United States
Rainier Clinical Research Center
Renton, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SBI-018-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.